The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand. Both Amgen's Bkemv and Teva/Samsung Bioepis' Epysqli ...

A digital therapy that could reduce the severity of chronic tic disorders like Tourette syndrome has been recommended for use by the NHS for the first time. The technology, known as ORBIT (Online ...

Investor panic has poleaxed Quince Therapeutics share price, after a regulatory filing revealed the biotech's cash is running out and it may have to file for bankruptcy protection. Shares in the South ...

In another major setback for abortion care in the US, a US court has issued an order restricting the distribution of ...

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's ...

In its first meeting for months, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted against AstraZeneca's oral ...

Moderna saw its first-quarter revenues nearly triple to $389 million compared to the same period of 2025, with international ...

In a statement, Prime Minister Keir Starmer said the "significant investment" had been "made possible by the pharmaceutical ...

Avalyn Pharma has priced its initial public offering (IPO) on the Nasdaq, hoping to raise an upscaled $300 million for its ...

From chip giant NVIDIA agreeing a $2 billion partnership with AI cloud provider Nebius, to Roche ramping up its investment in ...

As Parkinson’s Awareness Month comes to a close, the urgency to challenge the status quo has never been greater. With nearly ...

Contract research organisation Parexel has bought Vitrana and its AI-powered pharmacovigilance platform for an undisclosed ...